Teva Begin Period Cash Flow from 2010 to 2024
| TEVA Stock | USD 21.77 0.00 0.00% |
Begin Period Cash Flow | First Reported 2001-03-31 | Previous Quarter 3 B | Current Value 2.3 B | Quarterly Volatility 1.2 B |
Check Teva Pharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Teva Pharma's main balance sheet or income statement drivers, such as Depreciation And Amortization of 1.2 B, Interest Expense of 1.1 B or Total Revenue of 9.5 B, as well as many indicators such as Price To Sales Ratio of 0.7, Dividend Yield of 0.0042 or PTB Ratio of 1.48. Teva financial statements analysis is a perfect complement when working with Teva Pharma Valuation or Volatility modules.
Teva | Begin Period Cash Flow |
Latest Teva Pharma's Begin Period Cash Flow Growth Pattern
Below is the plot of the Begin Period Cash Flow of Teva Pharma Industries over the last few years. It is the amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities. Teva Pharma's Begin Period Cash Flow historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Teva Pharma's overall financial position and show how it may be relating to other accounts over time.
| Begin Period Cash Flow | 10 Years Trend |
|
Begin Period Cash Flow |
| Timeline |
Teva Begin Period Cash Flow Regression Statistics
| Arithmetic Mean | 2,053,113,333 | |
| Geometric Mean | 1,329,128,093 | |
| Coefficient Of Variation | 77.99 | |
| Mean Deviation | 1,048,520,889 | |
| Median | 1,975,000,000 | |
| Standard Deviation | 1,601,314,730 | |
| Sample Variance | 2564208.9T | |
| Range | 6.9B | |
| R-Value | 0.28 | |
| Mean Square Error | 2548802.4T | |
| R-Squared | 0.08 | |
| Significance | 0.32 | |
| Slope | 99,363,929 | |
| Total Sum of Squares | 35898924.1T |
Teva Begin Period Cash Flow History
About Teva Pharma Financial Statements
Teva Pharma stakeholders use historical fundamental indicators, such as Teva Pharma's Begin Period Cash Flow, to determine how well the company is positioned to perform in the future. Although Teva Pharma investors may analyze each financial statement separately, they are all interrelated. For example, changes in Teva Pharma's assets and liabilities are reflected in the revenues and expenses on Teva Pharma's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Teva Pharma Industries. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Begin Period Cash Flow | 2.8 B | 3 B |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Teva Pharma Industries offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Teva Pharma's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Teva Pharma Industries Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Teva Pharma Industries Stock:Check out the analysis of Teva Pharma Correlation against competitors. You can also try the Fundamental Analysis module to view fundamental data based on most recent published financial statements.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Teva Pharma. If investors know Teva will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Teva Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.4 | Earnings Share (0.85) | Revenue Per Share 14.879 | Quarterly Revenue Growth 0.125 | Return On Assets 0.0556 |
The market value of Teva Pharma Industries is measured differently than its book value, which is the value of Teva that is recorded on the company's balance sheet. Investors also form their own opinion of Teva Pharma's value that differs from its market value or its book value, called intrinsic value, which is Teva Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Teva Pharma's market value can be influenced by many factors that don't directly affect Teva Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Teva Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Teva Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Teva Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.